Nipro newsletter April 2026
Carterra 23/09/25
LB Bohle – 10.06.2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

DDL 2026
Merxin March 2026
Terumo 05/01
SAE Media – Pre-filled syringes West Coast 19/11/25
Nipro April 2026

Unreasonable prescription costs leading to life-threatening asthma attacks

Asthma UK has revealed that people with asthma are rationing their medication due to prescription costs and it’s causing avoidable asthma attacks and extra hospital admissions.

A new report by the charity has claimed that more than a million people in England are having to ‘pay to breathe’ and are at risk of having a life-threatening asthma attack because they are struggling to pay for their asthma prescriptions.

The news comes in light of a new campaign to stop unfair asthma prescription charges, which has revealed that of the 2.3 million people in England with asthma who have to pay for prescriptions, more than three quarters say they struggle to afford them.

‘Paying to breathe: Why unfair asthma prescription charges must be stopped’, which includes research with over 9,000 people with asthma in England, also revealed that more than half (57%) of people with asthma who pay for their medication have skipped taking it because of the cost, which adds up to an estimated 1.3 million people.

Of these, a quarter said it led to an asthma attack, and more than one in 10 said they had needed hospital treatment.

Dr Samantha Walker, director of research and policy at Asthma UK commented: “It is unfair that millions of people with asthma are getting a raw deal, paying unfair costs for their medicine just to stay well. No one should have to pay to breathe.

“Asthma is a serious condition that kills three people every day in the UK and the best way for people to stay well is to take their life-saving medication, often for their entire life.

“When people are struggling financially they may feel they simply cannot afford to pay for the medication. By not taking it, they are at risk of being hospitalised or even dying from an asthma attack.”

SMI London
Biopharma group march 2026
Silgan March 2026
Scott Pharma – 25.03.2025
Bespak – 21.05.2025
Aptar – 08/01/2026
Stoelzle – 15th May 2025
L.B. Bohle – 08.04.2025